Drug General Information
Drug ID	D0DM6I
Former ID	DIB010305
Drug Name	DAPITANT
Drug Type	Small molecular drug
Indication	Pain [ICD9: 338, 356.0, 356.8,780; ICD10:G64, G90.0, R52, G89]		Phase 2	[525747]
Structure		Download 2D MOL 3D MOL
Formula	C37H39NO4
Canonical SMILES	COc1ccccc1[C@H](C)C(=O)N2C[C@@H]3[C@H](C2)C(CC[C@@]3(O)<br />c4ccccc4OC)(c5ccccc5)c6ccccc6
InChIKey	CCIWVEMVBWEMCY-RCFOMQFPSA-N
CAS Number	CAS 153438-49-4
PubChem Compound ID	70695626
Target and Pathway
Target(s)	Substance-P receptor	Target Info	Antagonist	[545693], [551871]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Measles
PANTHER Pathway	CCKR signaling map ST
Reactome	G alpha (q) signalling events
WikiPathways	SIDS Susceptibility Pathways
	Gastrin-CREB signalling pathway via PKC and MAPK
	Spinal Cord Injury
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 525747	Dapitant. RPR 100893. Drugs R D. 1999 Dec;2(6):383-4.
Ref 545693	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004225)
Ref 551871	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.